I. 1. The Human Microbiota and Its Management – Clinical Frameworks

Your body is a microbial ecosystem; when its balance collapses, FMT aims not to kill a pathogen but to rebuild the whole community.

Building a New Life, One Microbe at a Time – Why This Handbook Exists

The scientific consensus now views the human body as an ecosystem in which microbes actively participate in digestion, immune regulation, and a wide range of metabolic processes extending far beyond the gastrointestinal tract. This microbial community is vast: the human gut alone harbours approximately 3.8×10¹³ bacterial cells (approximately 1:1 with host cells) representing more than 1,000 species at the population level (200–300 species coexisting in any individual) – their combined metagenome is roughly 150 times larger than the human genome itself [1], [2]. This community – the gut microbiota^[G] – is not a passive bystander in human health, but an active participant in processes including short-chain fatty acid production, bile acid metabolism, immune system education, neuroactive metabolite synthesis, and colonisation resistance against pathogens^[G].

We now recognise that the human body is a superorganism: a complex, dynamically interacting ecosystem of human cells and trillions of microbial organisms. The disruption of this ecosystem – known as dysbiosis – is associated with a broad range of conditions extending well beyond gastrointestinal disease: metabolic syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), autoimmune conditions, mood disorders, and susceptibility to recurrent infections [3], [4]. The therapeutic implication is clear: restoring a disrupted system to a stable, functional state carries measurable clinical consequences.

The clinical objective of this guide is to support microbiota^[G] restoration in patients with dysbiosis-associated conditions, through faecal microbiota transplantation and structured lifestyle interventions connected to it. This handbook provides the scientific background, the still preliminary clinical protocols, and the practical tools for every stage of the process.

It is important to emphasise that this handbook is not promotional material, but a practical clinical and scientific reference. Every claim it contains is supported by peer-reviewed literature; references are provided at the end of each chapter. Recommendations are graded by evidence strength, and well-established guidance is explicitly distinguished from areas resting on emerging or preliminary evidence, which are nevertheless equally important. Where individual clinical judgement is required, this guide expressly directs the reader to consult their treating clinician.

Dysbiosis – The Ecological Imbalance Associated with Many Conditions

A disrupted microbiota, known as dysbiosis, is not a disease entity but an ecological imbalance — a functional state. Dysbiosis^[G] can manifest as:

• Reduced microbial diversity, impairing resilience and metabolic redundancy;
• Overgrowth of opportunistic species (e.g., Clostridioides difficile (formerly Clostridium difficile));
• Functional dysregulation, where microbial metabolic output is abnormal even if community composition appears superficially intact.

The causal direction between dysbiosis and these conditions is not always established; in many cases they mutually reinforce one another: the disrupted bacterial matrix amplifies inflammation and metabolic dysfunction, which in turn further destabilises the microbiota [5]. Interrupting this cycle – through ecological restoration rather than symptom suppression alone – is the therapeutic rationale for FMT and the lifestyle interventions described in this guide.

It is worth introducing the contrasting concept: eubiosis. In this balanced state, the intestinal community maintains high species diversity, functional metabolic activity, and colonisation resistance – the capacity to prevent pathogen establishment through competitive exclusion and metabolite-mediated suppression. Eubiosis (a balanced gut microbiota state characterised by high diversity and functional stability) is not a fixed endpoint or a defined composition; it is a dynamic functional state that each individual's microbiota can achieve through different routes, depending on genetic background, dietary patterns, and environmental history [6]. The interventions described in this guide aim to create the conditions under which eubiosis can re-emerge and be sustainably maintained.

In this context, the use of antibiotic therapy as a method of treating infection becomes a paradox: it eliminates pathogens while simultaneously further damaging the ecological infrastructure of colonisation resistance. This paradox is most acute in recurrent C. difficile infection, where each antibiotic course suppresses the pathogen while removing the competitive microbial populations that would prevent its return – creating a cycle of recurrence that antibiotics alone cannot break [7]. FMT addresses this paradox directly: by reintroducing the ecological community, rather than simply targeting the pathogen.

FMT – Ecological Restoration, Not Just a Procedure

The FMT preparations – including phase-specific ones for hospital-based induction, CDI treatment, compatibility assessment, and consolidation – are designed to deliver diverse, screened donor microbial communities into the recipient's intestinal tract. The therapeutic effect of FMT, however, extends beyond bacterial recolonisation. The transplant carries metabolites, bacteriophages, immunomodulatory compounds, and the functional ecological relationships between species that confer resilience properties to the community. We refer to this system as the microbiota matrix. This complexity explains why FMT outperforms probiotic supplementation in severe dysbiosis: it delivers not isolated strains, but an integrated community with established competitive and metabolic dynamics [7], [8].

A successful transplant, however, is not merely about delivering microbes. It is also about creating and maintaining the favourable ecological conditions in which the incoming community can establish itself, remain competitive, and integrate. This is the foundational logic of treatment protocols: the FMT intervention is embedded within a structured framework of compatibility assessment, induction, consolidation, and step-down phases, each optimising different aspects of ecological restoration. This protocol is described in detail in Chapter II of this guide.

The evidence base for FMT is strongest in recurrent C. difficile infection, where cure rates of 81–94% (81% single dose, 94% after repeat dose) have been documented across multiple randomised controlled trials [7], [9]. In chronic non-CDI conditions – including inflammatory bowel disease, metabolic syndrome, and functional gastrointestinal disorders – the evidence is more variable, and the treatment protocol correspondingly more complex, requiring longer consolidation and careful compatibility assessment. Chapter II also details the scientific basis for these protocol differences.

The Exposome – The Environment That Determines Whether FMT Succeeds

Beyond capsules, the greatest determinant of microbiota colonization success is the patient themselves – or more precisely, their exposome. The exposome^[G] is the totality of all environmental exposures an individual experiences throughout their lifetime: diet, physical activity, sleep, stress, medications, chemical exposures, and social environment [10], [11]. All of these factors can nourish or disrupt the microbial ecosystem. For example:

• Antibiotics eliminate pathogens but simultaneously disrupt the structural and functional integrity of the commensal microbial community, abolishing colonisation resistance alongside the target pathogen.
• Processed foods and dietary additives promote dysbiosis, while dietary fibre provides the fermentable substrate that sustains SCFA^[G]-producing taxa essential for mucosal health and immune regulation.
• Chronic stress and poor sleep directly affect the gut-brain axis, modifying microbial composition through cortisol-mediated motility changes, increased epithelial permeability, and behavioural shifts in diet and physical activity.

In the FMT context, the exposome has a specific and measurable clinical role: it defines the ecological conditions into which the donor community is introduced, and within which it must compete and establish. The environmental factors that support the incoming community – adequate dietary fibre, regular sleep, moderate physical activity, controlled stress, minimal unnecessary antibiotic exposure – substantially increase the probability of durable FMT engraftment^[G]. The exposome that works against the incoming community creates conditions favouring the resurgence of dysbiosis-promoting species and ecological regression.

Clinically, gradual correction of diet, sleep, stress, and medication load more reliably supports microbial resilience than abrupt or extreme interventions. The Exposome Assessment Questionnaire completed at the end of Phase 0 compatibility assessment (the D•E•M•I questionnaire, introduced in Chapter III.2) is the structured clinical instrument with which the treating clinician maps each patient's individual exposome profile before induction, identifying the barriers and enabling factors whose management can optimise the conditions for FMT. The chapters following the FMT protocol section of this guide describe each major exposome domain in detail, with specific recommendations ranked by evidence strength.

How to Use This Guide – The Structure of the FMT Recovery Programme

This guide follows the patient's clinical journey from the pre-FMT period through to the long-term maintenance of the restored ecosystem. It is not intended to be read from start to finish in a single sitting; it is a reference document, to be used chapter by chapter as treatment progresses. The table below summarises the guide's structure and its relationship to the clinical protocol phases.

Table 1 – Guide chapter structure and clinical protocol mapping # Chapters III.1–III.7 cover the complete FMT protocol; the exposome chapters (IV–XIV) are applied in parallel throughout the treatment period.

Four principles govern how to use this guide most effectively:

• Follow the protocol sequence. Read the Chapter II subsections in the order listed; do not skip ahead – each section builds on the previous one.
• Coordination between the clinical team and the patient is essential. This guide is a complement to clinical treatment, not a substitute. Where any discrepancy exists between this guide and any clinician's instructions, those instructions always take precedence. This guide is intended to support understanding of the rationale behind clinical decisions, not to enable independent clinical decision-making by any patient.
• Use of the Food and Symptom Diary from day one is recommended. The FMT protocol chapters reference the Food and Symptom Diary throughout, which is the primary clinical monitoring tool for every phase of treatment. Begin completing it before your first FMT dose and maintain it consistently. The quality of its entries directly affects the quality of clinical decisions made on your behalf.
• Introduce lifestyle changes incrementally. The exposome chapters (III–XI) describe multiple concurrent intervention domains. Do not attempt to change everything at once. Prioritise the changes your clinical team recommends, in the order they specify, based on your individual exposome profile. Each new behavioural pattern should be applied and consolidated within a 14–21 day integration window.

All other chapters are reference material. They are organised so that one can navigate to the topic most relevant to the current situation – whether that is a dietary question, a medication concern, or an environmental factor to be understood.

A Final Thought – Health Is an Ecosystem, Not a Battlefield

The key message of this handbook is simple: health is not the absence of microbes, but the presence of a balanced microbial life. The therapeutic model embodied in this guide is ecological, not eliminative: rather than targeting the removal of pathogens, it restores the competitive community that makes pathogen establishment—and the transition of certain microbes into pathogenic states—impossible; rather than suppressing symptoms through pharmacological agents alone, it rebuilds the ecological infrastructure from which sustained remission can lastingly emerge. This is not a rejection of conventional medicine, but an extension of human biology into its ecological dimension.

Dysbiosis is not associated with a single disease – it is linked to many conditions, though the strength of evidence and causal relationships differ considerably by indication. Microbiota restoration is not about eliminating what is harmful, but about rebuilding what is beneficial. The FMT protocol, exposome interventions, and lifestyle guidance all serve this ecological purpose.

With this guide, FMT treatment, and deliberate lifestyle interventions, we are not merely treating a disease. We are creating the conditions for a more resilient and more diverse gut microbial community to emerge. The chapters that follow describe each step of this work.

References

[1] Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell. 2016. Link

Sender, Fuchs and Milo recalculated the widely cited 10:1 bacteria-to-human-cell ratio. Using updated data for a 70 kg reference man, they estimated about 3.8×10^13 bacteria versus about 3.0×10^13 human cells — a ratio close to 1:1 rather than 10:1, which a single defecation can shift in favour of human cells. The paper corrected a decades-old myth in microbiome science.

[2] Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010. Link

Illumina-based metagenomic sequencing of faecal samples from 124 European individuals (576.7 Gb of sequence) yielded a catalogue of 3.3 million non-redundant microbial genes, approximately 150-fold larger than the human gene complement. Genes were largely shared across individuals, with over 99\% bacterial origin. The cohort harboured an estimated 1,000–1,150 prevalent bacterial species, each individual carrying at least 160 species. The study defines a minimal gut metagenome and a minimal gut bacterial genome based on functions present in all individuals and most bacteria. Findings establish a foundational reference for the genetic potential of the human gut microbiota.

[3] Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The Human Microbiome Project. Nature. 2007. Link

Strategic framework outlining the Human Microbiome Project's approach to characterizing the microbial components of the human genetic and metabolic landscape. The initiative aims to establish how microbiota contribute to normal physiology and predisposition to disease. Serves as the foundational programmatic statement for large-scale population-level microbiome research.

[4] Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016. Link

Lynch and Pedersen provide a comprehensive New England Journal of Medicine review on the human intestinal microbiome in health and disease. They summarize the composition and stability of the adult microbiota, the major bacterial phyla (Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria), and the impact of host genetics, diet, antibiotics and birth mode on community structure. Mechanistic sections cover short-chain fatty acid production, bile acid metabolism, immune education, and barrier maintenance. Disease associations are reviewed for IBD, obesity, type 2 diabetes, atherosclerosis, allergy, and Clostridioides difficile infection. The article frames the microbiome as a tractable therapeutic target via diet, prebiotics, probiotics and fecal microbiota transplantation.

[5] Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016. Link

Mechanistic review of how the intestinal microbiome integrates environmental inputs (diet) with genetic and immune signals to influence host metabolism, immunity, and infection response. Haematopoietic and non-haematopoietic innate immune cells at the host–microbiome interface sense microorganisms and their metabolites, translating these signals into physiological responses and microbial ecology regulation. Disruption of this innate immune–microbiota communication is implicated in complex disease pathogenesis. The review frames the microbiome as a central signalling hub coordinating host defence and homeostasis.

[6] Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012. Link

Conceptual review describing the human gut as a complex ecological community whose collective metabolic activities and host interactions influence physiology and disease susceptibility. The gut microbiota is highly diverse, varies between individuals, and fluctuates over time, particularly during disease and early development. The authors argue that an ecological framework — addressing diversity, stability, and resilience — is necessary for designing effective microbiota-targeted therapies. The paper provides a theoretical foundation for clinical microbiome modulation strategies.

[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link

Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.

[8] Ianiro G, Punčochář M, Karcher N et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat Med. 2022. Link

Integrated shotgun metagenomic meta-analysis of 226 donor–recipient triads across eight disease types examining microbial engraftment dynamics after FMT. Higher donor strain engraftment was significantly associated with clinical success (P=0.017). Engraftment was greater with multi-route delivery (capsule plus colonoscopy) and in antibiotic-treated recipients with infectious disease versus antibiotic-naïve patients with noncommunicable disease. Bacteroidetes and Actinobacteria (including Bifidobacteria) showed higher engraftment than most Firmicutes. A cross-dataset machine-learning model predicted post-FMT species presence with AUROC 0.77.

[9] Peery AF, Kelly CR, Kao D et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024. Link

AGA clinical practice guideline using the GRADE framework to address fecal microbiota-based therapies (conventional FMT, fecal microbiota live-jslm, fecal microbiota spores live-brpk) in adults with recurrent or severe-to-fulminant Clostridioides difficile infection, IBD/pouchitis, and IBS. The panel issued 7 recommendations. In immunocompetent adults with recurrent CDI, the AGA suggests selective use of fecal microbiota-based therapies after standard-of-care antibiotics to prevent further recurrence. Provides framework guidance integrating FDA-approved products with conventional FMT.

[10] Wild, C. P. Complementing the Genome with an 'Exposome': The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology. Cancer Epidemiol Biomarkers Prev. 2005. Link

Wild's seminal 2005 Cancer Epidemiology, Biomarkers and Prevention commentary introduces the concept of the 'exposome' to complement genomic measurement in molecular epidemiology. He argues that lifetime environmental exposures, including diet, lifestyle, infections, pollutants and endogenous processes, are as important as the genome in determining disease risk, but are systematically under-measured. The article calls for technologies and study designs capable of capturing exposures across the life course with sensitivity comparable to high-throughput genomics. Wild outlines internal, specific-external and general-external exposome domains. The concept has since shaped large cohort studies and biomarker-based exposure assessment, including microbiome-related work.

[11] Rappaport SM, Smith MT. Epidemiology. Environment and Disease Risks. Science. 2010. Link

Conceptual statement arguing that a new epidemiological paradigm is required to assess how lifetime cumulative exposure to environmental factors affects chronic disease risk. Calls for systematic exposome-level analysis beyond single-exposure designs.